Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell
carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance …

Tyrosine kinase inhibitors (TKI) targeting angiogenesis via inhibition of the vascular
endothelial growth factor pathway have changed the medical management of metastatic …

The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

The introduction of agents that inhibit tumor angiogenesis by targeting vascular endothelial
growth factor (VEGF) signaling has made a significant impact on the survival of patients with …

As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a
most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma …

Sunitinib is a broad-spectrum small-molecule inhibitor of receptor tyrosine kinases (RTK)
that serves as the present standard of care for first-line therapy of advanced clear cell renal …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Purpose Concurrent inhibition of multiple oncogenic signaling pathways might improve the
efficacy of anticancer agents and abrogate resistance mechanisms. This phase I study …

Alternative pathways to the VEGF, such as hepatocyte growth factor or HGF/c-met, are
emerging as key players in tumor angiogenesis and resistance to anti-VEGF therapies. The …

Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …